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STUDENT COMMENT
TWO & A HALF PARENTS: THREE-PARENT IVF AND MEDICAL
MALPRACTICE IN THE UNITED STATES
Jay M. Fulk*
Fertility medicine is seeing a rapid advancement with the emergence
of a new procedure called three-parent in vitro fertilization (IVF). This novel
procedure provides an opportunity for women who have defective
mitochondria to bear their own healthy genetic children. As women
encounter fertility issues, they will often turn to regular IVF by receiving an
egg from a donor—ultimately resulting in a child with no genetic relation to
the mother.
Women with defective mitochondria will likely pass down a
mitochondrial disease to their children, therefore, bearing a child without the
assistance from a donor does not present a viable option. Mitochondrial
disease can be quite severe and traumatic, usually affecting the central
nervous system. It can contribute to many serious illnesses such as
Parkinson’s, Alzheimer’s, and cancer. Currently, there are no treatment
options available for people with mitochondrial disease. Regular IVF
requires an egg from a donor to replace the mothers egg, therefore, the
mother is not genetically related to the child she bears, as the egg donor is
the genetic mother. Three-parent IVF is a breakthrough fertility treatment
procedure that allows women with defective mitochondria to bear a healthy
child by receiving healthy mitochondria from a donor. This procedure
enables women to retain a genetic bond to their child. Since a donor’s healthy
mitochondria is transferred to the mother’s egg, the child will technically
have three genetic parents (two mothers and a father).
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Three-parent IVF is currently not allowed in the United States, but
with responsible legislation, it could be legal in the near future. This
Comment proposes that three-parent IVF is implemented as a clinical trial
for the purposes of conducting research to assess for safety and effectiveness.
Current safety regulations and guidelines, primarily those regarding human
tissue donation and transplantation, are quite instructive when put in the
three-parent IVF context. These regulations and guidelines are discussed in
some detail. There are a couple of steps that need to be taken in order to
successfully implement three-parent IVF in the United States. First, great
strides need to be made to reform the broken medical malpractice system in
the United States. Current medical malpractice standards, and the available
remedies to fertility plaintiffs, are not adequate to accommodate such a
procedure. This Comment proposes that we move away from the customary
care standard, and towards an evidence-based standard of care, while
adopting the reasonable patient standard of informed consent. These
standards will help address the inefficiency problems that exist within the
medical profession. Second, since medical malpractice lawsuits are too
costly for most fertility plaintiffs to pursue, there needs to be a fertility court
established within the United States Court of Federal Claims—following in
the successful footsteps of vaccine court. A fertility court will give fertility
plaintiffs a remedy when they are injured by a doctor’s negligence, when no
such remedy would have otherwise been available. Also, the establishment of
a fertility court will lower fertility doctor’s medical malpractice premiums by
reducing their overall litigation liability—as fertility plaintiffs will primarily
turn to fertility court to redress their injuries.
The United Kingdom is leading the world into the future by being the
first country to approve the three-parent IVF procedure. The time has come
for the United States to take a serious look at three-parent IVF to help
advance fertility medicine into a promising and hopeful future.
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INTRODUCTION
A revolution is currently underway. Three-parent in vitro
fertilization1 (IVF) has burst onto the scene within reproductive health over
1

In Vitro Fertilization (IVF), MAYO CLINIC, https://www.mayoclinic.org/tests-procedures/in
-vitro-fertilization/home/ovc-20206838 (last visited Feb. 24, 2018). Here is a brief and
concise overview of IVF:
In vitro fertilization (IVF) is a complex series of procedures used to treat
fertility or genetic problems and assist with the conception of a child.
During IVF, mature eggs are collected (retrieved) from [the] ovaries and
fertilized by sperm in a lab. Then the fertilized egg (embryo) or eggs are
implanted in [the] uterus. One cycle of IVF takes about two weeks. IVF is
the most effective form of assisted reproductive technology. The
procedure can be done using [the females] own eggs and [her] partner’s
sperm. Or IVF may involve eggs, sperm or embryos from a known or
anonymous donor. In some cases, a gestational carrier—a woman who has
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the last few years, which has sparked rigorous discussion and debate. In April
2016, the world said hello to the first child conceived using three-parent IVF.2
A couple from Jordan contacted Dr. John Zhang3 from New Hope Fertility
Center in New York to assist them in conceiving a healthy child.4 The woman
had “a condition called Leigh syndrome, a neurological condition that killed
her two prior children.”5 Since the genes that carried this disease were
transported within her mitochondrial DNA (mtDNA)—and since mothers
pass down their mitochondria to their children—the only way for her to have
a healthy child was a mitochondrial transplant.6 The baby boy was delivered
in Mexico, since the mitochondrial transplant procedure is currently not
allowed in the United States, and there are currently no regulations in place
for Mexico.7 While the procedure is still new, Dr. Zhang continues to discuss
his three-parent IVF activities—specifically about advertising the
procedure—in the United States with the Food and Drug Administration
an embryo implanted in her uterus—might be used. [The] chances of
having a healthy baby using IVF depend on many factors, such as [the
females] age and the cause of infertility. In addition, IVF can be timeconsuming, expensive and invasive. If more than one embryo is implanted
in [the] uterus, IVF can result in a pregnancy with more than one fetus
(multiple pregnancy).
Id.
2
Andrew Joseph, World’s First Baby Born with Novel Three-Parent Embryo Technique,
STAT (Sept. 27, 2016), https://www.statnews.com/2016/09/27/three-parent-baby-embryo/.
3
John Zhang, John Zhang, MD, MsC, PhD, NEW HOPE FERTILITY CTR., https://www.new
hopefertility.com/about-us/fertility-doctors/john-zhang/ (last visited Feb. 24, 2018). Dr.
John Zhang is a fertility specialist and the “Founder/CEO of New Hope Fertility Center in
New York City.” Id. He is considered to be a pioneer in the area of assisted reproductive
technology (ART). Id. He earned his medical degree from Zhejiang University School of
Medicine and his Ph.D. in In-Vitro-Fertilization (IVF). Id.
Today, Dr. Zhang continues his research in non-embryonic stem cell
research, long-term cryopreservation of oocytes, and oocyte (human egg
cell) reconstruction by nuclear transfer. He is currently one of a handful of
Reproductive endocrinologists in the United States to hold a Ph.D. in
embryology while also being certified as a High Complexity Lab Director.
Id.
4
Joseph, supra note 2.
5
Id.
6
James D. McCully et al., Mitochondrial Transplantation: From Animal Models to Clinical
Use in Humans, 34 MITOCHONDRION 127, 127 (2017) (“Mitochondrial transplantation is a
novel therapeutic intervention to treat . . . disorders. The method for mitochondrial
transplantation is simple and rapid and can be delivered to the end organ either by direct
injection or vascular infusion.”).
7
Joseph, supra note 2.
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FDA).8 In January 2017, the first girl9 conceived using the three-parent IVF
procedure was born in Kiev, Ukraine.10
When confronted with fertility issues, women often turn to Assisted
Reproductive Technology (ART).11 Fertility treatments can take many forms:
ART is used to treat infertility. It includes fertility treatments
that handle both a woman’s egg and a man’s sperm. It works
by removing eggs from a woman’s body. The eggs are then
mixed with sperm to make embryos. The embryos are then put
back in the woman’s body. In vitro fertilization (IVF) is the
most common and effective type of ART.12

8

Susan Scutti et al., FDA Warns ‘3-Parent’ Baby Fertility Doctor Over Marketing, CNN
(Aug. 7, 2017, 10:49 AM), http://www.cnn.com/2017/08/07/health/fda-3-parent-fertilityzhang/index.html. Since Dr. Zhang performed the three-parent IVF procedure in Mexico, he
has been advertising three-parent IVF as a service offered by New Hope Fertility Center. Id.
The FDA sent Dr. Zhang a letter, warning him that marketing the technique is not authorized
by the FDA because three-parent IVF has not been authorized to be used on human beings
in the United States. Id.
Mary A. Malarkey, the director of the FDA’s Office of Compliance and
Biologics Quality at the agency’s Center for Biologics Evaluation and
Research, said Zhang had submitted a written request dated April 22, 2016,
“asking for a pre-investigational new drug (IND) meeting for a clinical
investigation of a ‘spindle transfer for assisted pregnancy in patients with
mitochondrial disease.’”
Id. The FDA rejected the request citing “Congress’ prohibition on the use of funds to accept
IND submissions for clinical investigations that involve a human embryo being
‘intentionally created or modified to include a heritable genetic modification.’” Id.
9
Susan Scutti, First Three-Parent Baby Girl Born Using Controversial IVF Technique, CNN
(Jan. 18, 2017, 4:08 PM), https://www.cnn.com/2017/01/18/health/ivf-three-parent-babygirl-ukraine-bn/index.html. The sex of the embryo could have significant ramifications,
which has sparked an ethical debate. Id. Doctors in Kiev, Ukraine, helped a previously
infertile couple conceive and deliver a baby girl using three-parent IVF. Id. According to
Lori P. Knowles, adjunct professor at the University of Alberta School of Public Health,
skeptics are arguing that if three-parent IVF is going to be utilized, it should be limited to a
male embryo. Id. A male baby “carrying donor mitochondria cannot pass their modified
genetics onto any future children they may have because once a sperm fuses with an egg to
form an embryo, the masculine mitochondrion withers and dies leaving the resulting embryo
with only mitochondrion from the mother’s egg.” Id. Speaking about the baby girl born in
Ukraine, Ms. Knowles states: “I do think it’s highly significant that this is a girl because we
know for sure that she will be passing on her mitochondrial DNA through her maternal
line[.]” Id.
10
Id.
11
Assisted Reproductive Technology, MEDLINE PLUS, https://medlineplus.gov/assistedrepro
ductivetechnology.html (last visited Feb. 24, 2018).
12 Id.
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Most people have heard about regular IVF, which is a procedure designed to
assist women who have fertility issues to become pregnant through egg
donation.13 Although the mother bears the child,14 she is not genetically
related to the child, as the egg comes from a third-party donor. Three-parent
IVF provides a remedy for women with fertility issues who long to be
genetically related to their child.
This Comment will discuss the two different infertility-causing
conditions that can be remedied by mitochondrial transplants: “aged eggs”15
and mitochondrial disease.16 Three-parent IVF remedies both issues for
women by allowing the mother to receive assistance from a donor while
maintaining a genetic bond with her child. The three-parent IVF procedure
essentially results in a child with three genetic parents, hence its name.17
Exciting as it may sound, three-parent IVF is currently not allowed in the
13

In Vitro Fertilization (IVF), JOHNS HOPKINS MED., http://www.hopkinsmedicine.org
/fertility/services /ivf/index.html (last visited Feb. 24, 2018).
14
Bearing, MERRIAM-WEBSTER, https://www.merriam-webster.com/dictionary/bearing (last
visited Feb. 24, 2018) (meaning “the act, power, or time of bringing forth offspring”).
15
Aging Eggs: Exciting Research is on the Horizon, FERTILITY AUTHORITY, https://www.f
ertilityauthority.com/articles/aging-eggs-exciting-research-horizon(last visited Feb. 24,
2018). Aging takes a toll on the human body and a female’s eggs are no exception:
We get tired as we age, and so do our eggs—the oocytes don’t have enough
energy to go through the rapid cell division for fertilization. It becomes
harder to get pregnant naturally and through fertility treatments such as in
vitro fertilization (IVF). These aging eggs are more likely to have
chromosomal abnormalities known as aneuploidy, less likely to develop
into embryos once fertilized, and if they do develop, they are more likely
to not implant or be lost through miscarriage.
Id.
16
Mitochondrial Disease, MEDICINENET.COM, https://www.medicinenet.com/mitochondrial
_disease/article.htm (last visited Nov. 26, 2017). Mitochondrial disease greatly affects the
human body’s ability to function properly:
Mitochondrial disease includes a group of neuromuscular diseases caused
by damage to intracellular structures that produce energy, the
mitochondria. . . . Mitochondrial myopathies are a group of neuromuscular
diseases caused by damage to the mitochondria—small, energy-producing
structures that serve as the cells’ “power plants.” Nerve cells in the brain
and muscles require a great deal of energy, and thus appear to be
particularly damaged when mitochondrial dysfunction occurs.
Id.
17

Bob Zhao, Mitochondrial Replacement Therapy and the Regulation of Reproductive
Genetic Technologies in the United States, 15 DUKE L. & TECH. REV. 121, 123 (2017).
Three-parent IVF results in DNA from the mother and father, along with the mitochondrial
DNA from the donor. Id.
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United States. The global discussion about three-parent IVF is on the rise, as
the United Kingdom has recently passed legislation to allow the procedure.18
This rise in global awareness gives the United States a prime opportunity to
take a hard look at the procedure. The question then becomes: What is the
liability associated with three-parent IVF procedures when the inevitable first
injury occurs within the United States?
Consider the following hypothetical: John and Mary have been
married for 18 years and are interested in starting a family together. They are
both in their late 40s, and Mary has enjoyed a career as an attorney for the
last 15 years. Mary made the conscious choice to pursue a career before
establishing a family, but that choice has put her in a difficult position. Her
mtDNA is defective due to her age (“aged eggs”19), and as a result, she will
likely be unable to become pregnant. Mary yearns to be genetically attached
to her child, so she rules out regular IVF and adoption. John, a physician,
hears about three-parent IVF through a colleague and decides to look into it.
He contacts a fertility specialist who performs three-parent IVF procedures,
and the specialist informs them of a new clinical trial that was just approved.
John and Mary meet with the fertility specialist, who is willing to perform the
procedure. Mary signs an informed consent form to go ahead with the
procedure; during the procedure, the fertility specialist makes crucial
mistakes, causing serious complications with the embryo. The child is born
with multiple issues—all attributable to the fertility specialist’s failure to use
reasonable care in the process. John and Mary are now wondering what the
fertility specialist’s liability for the procedure will be if they file a medicalmalpractice lawsuit against him.
The purpose of this Comment is to explore the relationship between
three-parent IVF and medical malpractice in the United States. The first
section begins with a basic scientific overview of three-parent IVF. It then
transitions into the current professional standards pertaining to care and
informed consent—primarily as they apply to the doctor-patient relationship.
A discussion follows in the third section regarding the current regulatory
climate for safety within the human-based product industry and within the
medical profession itself. This Comment concludes by proposing the
18

Kate Kelland, For the First Time, U.K. Allows Clinic to Proceed with “3-Parent” Baby
Procedure, SCI. AM. (Mar. 16, 2017), https://www.scientificamerican.com/article/for-thefirst-time-u-k-allows-clinic-to-proceed-with-3-parent-baby-procedure/.
19
See supra note 15 and accompanying text.
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implementation of three-parent IVF as a clinical trial so that physicians,
scientists, and researchers can monitor risks and outcomes. If the resulting
empirical evidence is satisfactory to legislators, the eventual goal is to fully
legalize the procedure in the United States—offering three-parent IVF to
patients who cannot utilize regular IVF or other means to satisfy their fertility
needs. This Comment recommends that the evidence-based standard of care
should be adopted, along with the reasonable patient standard of informed
consent, when it comes to dealing with three-parent IVF procedures in the
United States. Lastly, this Comment addresses the need to establish a fertility
court to assist injured plaintiffs in medical-malpractice lawsuits involving
three-parent IVF procedures.
I.
A.

THE SCIENCE

An Overview of Three-Parent IVF

“The field of reproductive technology is renowned for pushing
boundaries and contributing innovative approaches to the pursuit of fertility
enhancement.”20 Robert Edwards21 was the recipient of a Nobel Prize in
physiology and medicine for pioneering IVF—a procedure that ultimately
helped alleviate the mental and emotional pain associated with infertility.22
Unprecedented scientific breakthroughs are transforming reproductive
medicine as we know it.23 Human germline genetic modification (HGGM)

20

Zhao, supra note 16, at 121.
Robert Edwards was a fertility medicine pioneer, making many significant contributions
throughout his career—culminating in a Nobel Prize:
21

Sir Robert Geoffrey Edwards [was a] British medical researcher who
developed the technique of in vitro fertilization (IVF). Edwards, together
with British gynecologist Patrick Steptoe, refined IVF for the human egg.
Their work made possible the birth of Louise Brown, the world’s first
“test-tube baby,” on July 25, 1978. Edwards was awarded the 2010 Nobel
Price for physiology or Medicine for his discoveries.
Robert Edwards: British Medical Researcher, ENCYCLOPEDIA BRITANNICA, https://
www.britannica.com/bio graphy/Robert-Edwards (last visited Feb. 24, 2018).
22
Eli Y. Adashi, Fifty Years After Huxley: The Roadmap of Reproductive Medicine Revisited
and Updated: The 2015 SRI-Pardi Distinguished Scientist Plenary Lecture of the Society of
Reproductive Investigation, 22 REPROD. SCI. 1330, 1330 (2015).
23
Id.
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has the potential to play an instrumental role in these breakthroughs by
altering genes in sperm and embryos24 in fertility treatment.25
[HGGM] means deliberately changing the genes passed on to
children and future generations – in other words, creating
genetically modified people. [HGGM] has for many years
been widely considered off-limits, for both safety and social
reasons. It is formally prohibited in more than 40 countries.26
The human body is comprised of cells, each containing 46
chromosomes of DNA that provide the blueprint for the cell’s development
and function.27 Each cell contains a nucleus that houses human genetic
material, including mitochondria, which act as the cell’s “battery pack,” using
oxygen to create energy that powers the cell.28 Each cell contains mtDNA.29
24

Embryo, FREE DICTIONARY, https://medical-dictionary.thefreedictionary.com/embryo
(last visited Feb. 24, 2018). The definition of an embryo is as follows:
[A] new organism in the earliest stage of development. In humans this is
defined as the developing organism from the fourth day after fertilization
to the end of the eighth week. After that the unborn baby is usually referred
to as the fetus. . . . Immediately after fertilization takes place, cell division
begins and progresses at a rapid rate. At approximately 4 weeks the cell
mass becomes a recognizable embryo from 7 to 10 mm long with
rudimentary organs. The beginnings of the eyes, ears, and extremities can
be seen. By the end of the second month the embryo has grown to a length
of 2 to 2.5 cm, and the head is the most prominent part because of the rapid
development of the brain; the sex can be distinguished at this stage. At the
time of fertilization the ovum contains the potential beginnings of a human
being. As cell division takes place the cells of the blastoderm (embryonic
disk) gradually form three layers from which all the body structures
develop. The ectoderm (outer layer) gives rise to the epidermis of the skin
and its appendages, and to the nervous system. The mesoderm (middle
layer) develops into muscle, connective tissue, the circulatory organs,
circulating lymph and blood cells, endothelial tissues within the closed
vessels and cavities, and the epithelium portion of the urogenital system.
From the endoderm (internal layer) are derived those portions not arising
from the ectoderm, the liver, the pancreas, and the lungs.
Id.
25
Zhao, supra note 16, at 121–22.
26
About Human Germline Gene Editing, CTR. FOR GENETICS & SOC’Y (July 9, 2015),
https://www.geneticsand society.org/internal-content/about-human-germline-gene-editing.
27
J. Ravindra Fernando, Note, Three’s Company: A Constitutional Analysis of Prohibiting
Access to Three-Parent In Vitro Fertilization, 29 NOTRE DAME J.L. ETHICS & PUB. POL’Y
523, 528 (2015).
28
Id.
29
Ruth L. Fischbach et al., Creating a Three-Parent Child: An Educational Paradigm for
the Responsible Conduct of Research, 15 J. MICROBIOLOGY & BIOLOGY EDUC. 186, 186
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“Mitochondria are ‘responsible for providing more than 90% of the energy
needed by the body to sustain life and support growth.’”30
In reproduction, the egg and the sperm each carry half of the required
number of chromosomes and combine their nuclear DNA (nDNA)31 to create
a zygote,32 which divides to form an embryo.33 MtDNA, however, is unique
in that it is not created by a combination of the parents’ DNA.34 Instead,
individuals inherit mtDNA exclusively from their mothers.35 Although
mtDNA accounts for a very small percentage of the human genome,
mitochondrial gene mutations can cause severe neurological consequences.36
“Mitochondrial dysfunction has been recognized as a significant cause of a
number of serious multi-organ diseases. Tissues with a high metabolic
demand such as brain, heart, muscles, [and central nervous system] CNS are
often affected.”37 Health conditions that arise out of mitochondrial disease
can be due to mutations in mtDNA or in nuclear genes involved in
mitochondrial function.38 Mitochondrial disease may contribute to many
common and serious illnesses such as Alzheimer’s, Parkinson’s, diabetes,
arthritis, cancer, and premature aging.39 “There is no curative treatment for
patients with mitochondrial disease, [and] given the lack of treatments and
the limitations of prenatal and preimplantation diagnosis, attention has
focused on prevention of transmission of mitochondrial disease through
(2014).
30
Nicole Baffi, The Good, The Bad, and the Healthy: How Spindle-Chromosomal Complex
Transfer Can Improve the Future, 74 ALB. L. REV 361, 363 (2010).
31
Difference Between Mitochondrial DNA and Nuclear DNA, MAJOR DIFFERENCES, http://
www.majordifferences.com/2015/05/difference-between-mitochondrial-dna.html#.WhhZkyZPgo (last visited Feb. 24, 2018). Nuclear DNA (nDNA) makes up approximately 93% of
the total DNA in a human being. Id. It is made up of 3.3 billion DNA base pairs and codes
for all proteins required for its function. Id. nDNA is inherited equally between the parents,
unlike mtDNA, which is only inherited from the maternal line. Id.
32
Zygote, COLLINS, https://www.collinsdictionary.com/us/dictionary/english/zygote (last
visited Feb. 24, 2018) (“A zygote is an egg that has been fertilized by sperm, and which
could develop into an embryo.”).
33
ASSOC. OF REPROD. HEALTH PROF’LS, HUMAN CLONING AND GENETIC MODIFICATION:
THE BASIC SCIENCE YOU NEED TO KNOW 5, http://www.arhp.org/uploadDocs/cloning.pdf.
34
Fischbach et al., supra note 29, at 187.
35
Fernando, supra note 27, at 529.
36
Fischbach et al., supra note 29, at 187.
37
Paula Amato et al., Three-Parent IVF: Gene Replacement for the Prevention of Inherited
Mitochondrial Diseases, NAT’L CTR. FOR BIOTECHNOLOGY INFO. (Jan. 1, 2015), https://ww
w.ncbi.nlm.nih.gov/pmc/articles/PMC4005382/.
38
Id.
39
Baffi, supra note 30, at 361.
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[HGGM] therapy.”40 MtDNA mutations are difficult to identify within the
mother’s eggs because of the mutation’s inconsistent and erratic
nature.41 This has created a considerable challenge to find ways to prevent
mutated mtDNA from genetically transferring to the child.42 Approximately
1 in 4,000 children are born in the U.S. with an inherited mitochondrial
disease.43
B.

Mitochondrial Replacement Therapy

Mitochondrial Replacement Therapy (MRT) is an experimental ART
for women with “aged eggs”44 or mitochondrial disease who want to avoid
passing the disease to their children.45 Essentially, MRT involves transferring
DNA between two fertilized eggs, creating a new embryo containing the core
nDNA from the mother and father and the healthy mtDNA from a female egg
donor.46 This therapy results in a child with DNA from three different
people.47 There are two methods by which MRT can be performed: the
pronuclear transfer method and the maternal spindle transfer method.48
1.
Pronuclear transfer method. The pronuclear transfer method
involves removal of genetic material from an embryo created from the donor
sperm and egg, which is then replaced with genetic material from a second
embryo created from the paternal sperm and egg.49 First, the mother’s egg
(with mitochondrial disease) is fertilized with the father’s sperm, creating an
embryo.50 Second, the donor egg is fertilized with donor sperm and the nDNA
is removed—leaving behind the donor’s healthy mitochondria and also
creating an embryo.51 The final step is to transfer the nDNA from the
mother’s embryo to the donor embryo where the healthy mitochondria

40

Amato et al., supra note 37.
Baffi, supra note 30, at 362.
42
Id.
43
Amato et al., supra note 37.
44
See supra note 15 and accompanying text.
45
See supra note 15 and accompanying text.
46
Padmini Cheruvu, Three-Parent IVF and Its Effect on Parental Rights, 6 HASTINGS SCI.
& TECH. L.J. 73, 76 (2014).
47
Amy B. Leiser, Note, Parentage Disputes in the Age of Mitochondrial Replacement
Therapy, 104 GEO. L.J. 413, 414 (2016).
48
Id. at 420.
49
Cheruvu, supra note 46.
50
Id.
51
Id.
41
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remains.52 This provides a viable, healthy embryo with the nDNA of the
mother and father and the mtDNA of the donor.53
2.
Maternal spindle transfer method. Dr. Zhang, from New
Hope Fertility Center in New York, utilized the maternal spindle transfer
method (MST) for the Jordanian couple.54
[MST] involves placing nuclear material from the mother’s
egg into a donor egg “shell,” which contains healthy
mitochondria but no nDNA. In this method the egg is
fertilized with the father’s sperm in vitro, but not until after
the transfer occurs. Since an unfertilized egg is more
susceptible to damage, researchers believe that the more
complex pronuclear transfer method, which involves two in
vitro fertilizations, will be the preferred, future technique.55
The medical profession is highly regarded because of the significant
role it plays in the well-being of society. This high regard comes with high
standards: the imposition of heightened standards of care and informed
consent on the medical industry. Pronuclear transfer and maternal spindle
transfer are both methods used in three-parent IVF procedures that require
great care and diligence from the medical professionals administering the
procedures to patients. This next section will discuss those standards and how
they pertain to three-parent IVF.
II.

PROPER STANDARDS OF CARE AND INFORMED CONSENT FOR
MEDICAL PROCEDURES

Medical professionals are held to high standards, but those standards
are not always adequate for every medical procedure. There is a standard of
care that is practically universal to all physicians in the United States: the
customary care model.56 But, is this model sufficient for three-parent IVF
procedures? And, what role the patient should play when deciding for or
against a certain medical procedure? These are questions that must be
answered, especially within the context of three-parent IVF.
52

Tina Hesman Saey, How to Make a ‘Three-Parent’ Baby: Scientists Combined an Egg,
Sperm and Some Donor DNA to Create a Baby, SCI. NEWS FOR STUDENTS (Feb. 21, 2017
7:10 AM), https://www.sciencenewsfor students.org/article/how-make-three-parent-baby.
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Liat Clark, Three-Parent Babies: How are They Made and is the IVF Legal?, WIRED
(Jan. 18, 2017), http://www.wired.co.uk/article/what-is-three-person-ivf.
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Cheruvu, supra note 46, at 76 (footnotes omitted).
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BARRY R. FURROW ET AL., HEALTH LAW 265 (2nd ed. 2000).
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The Standards of Care in the United States

Judges and juries do not establish the standards by which medical
services are to be delivered to the public.57 In fact, these standards are created
solely by the medical professionals themselves, and courts simply enforce
these standards in lawsuits.58 A plaintiff has the burden to prove that the
doctor breached the standard of care, and most courts give conclusive weight
to that standard.59
Tom Baker, author of The Medical Malpractice Myth, states his
opinion relating to the seriousness of having correct standards of care in
place:
One very clear conclusion emerges from the research on
medical malpractice and medical malpractice lawsuits: The
real medical malpractice problem is medical malpractice. It is
not pretty to say, but doctors and nurses make preventable
mistakes that kill more people in the United States every year
than workplace and automobile accidents combined. Any
research-driven approach to medical liability reform must
start with this fact firmly in mind.60
This section will discuss the two standard of care models: the customary care
standard and the evidence-based standard.
Doctors are liable when they make certain mistakes. Society generally
demands that a doctor not be immune from liability to ensure quality
healthcare delivery. The customary care standard is used throughout the
country to determine a doctor’s liability.61 This custom-based standard of
care is the requisite degree of both care and skill, based on the medical
knowledge available, that a PR actioner in a provider’s specialty must
demonstrate.62 “Custom-based medical practice can have a profoundly
negative impact on the quality and cost of healthcare. . . . The customary care
(or eminence-based) model of medical practice is based on physician
57

Id.
Id.
59
Id.
60
TOM BAKER, THE MEDICAL MALPRACTICE MYTH 157 (reprt. 2007).
61
Katharine Van Tassel, Harmonizing the Affordable Care Act with the Three Main National
Systems for Healthcare Quality Improvement: The Tort, Licensure, and Hospital Peer
Review Hearing Systems, 78 BROOK. L. REV. 883, 884 (2013).
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David Goguen, What is the Medical Standard of Care?, ALLLAW, http://www.alllaw.
com/articles/nolo/medical-malpractice/standard-of-care.html (last visited Feb. 24, 2018).
58

2018

TWO & A HALF PARENTS

213

preference grounded in tradition, opinion, or clinical experience and not on
objective, scientific evidence.” 63 Conversely, the evidence-based standard of
care can have a positive impact on the quality and cost of healthcare because
it includes research, clinical expertise, and patient preferences and values.64
There are five ways that the evidence-based standard benefits the
healthcare system as a whole: (1) it helps physicians stay up-to-date on
standardized protocols that are evidence-based; (2) the standard requires near
real-time data for physicians to make health care decisions; (3) it promotes
transparency and accountability; (4) it improves the overall quality of care
administered; and (5) it has better clinical outcomes.65 Dr. John Haughom,
senior advisor of Health Catalyst University, described the necessary and
proper steps to be taken in evidence-based medicine.66 First, teams of
physicians must identify problems that need to be addressed, such as reducing

63

Van Tassel, supra note 61.
John Haughom, 5 Reasons the Practice of Evidence-Based Medicine is a Hot Topic,
HEALTHCATALYST, https://www.healthcatalyst.com/5-reasons-practice-evidence-based-me
dicine-is-hot-topic (last visited Feb. 24, 2018). The evidence-based standard of care brings
more efficiency to the healthcare system by incorporating meaningful patient involvement:
64

Practicing evidence-based medicine is important in today’s healthcare
environment because this model of care offers clinicians a way to achieve
the Triple Aim’s objectives of improved quality, improved patient
satisfaction, and reduced costs. To understand how, consider the prostate
cancer example. With evidence-based medicine, a provider can assess the
strength of the evidence as well as the risks and benefits of ordering
diagnostic tests and treatments for each cancer patient. Such an approach,
couples with the provider’s clinical experience, enables the provider to
better predict if a treatment will do more harm than good. It also helps the
organization establish a systematic approach to caring for patients with
specific conditions . . . . As reported in the article “The Importance and
Impact of Evidence-Based Medicine,” using evidence-based medicine
“help[s] physicians provide more rational care with better outcomes.”
Evidence-based medicine is not just about using evidence to design
treatment plans; It also encourages a dialogue between patients and
providers, so patients can share in the decision-making and make their
values and preferences known. Together, patient and provider can
determine an appropriate course of action—or no course of action if that’s
on the joint decision. The benefit of this approach is that providers listen to
patient concerns and take them into consideration to determine the
appropriate treatment plan.
Id.
65
Id.
66
Id.
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readmissions or some other high-priority problem.67 Some questions that
physicians can ask themselves are: Why are we practicing in this manner?
Are we adhering to best practices, and can we produce better outcomes with
more consistency? Second, the physicians must acquire the best possible
evidence that is available to them.
There are many different sources of evidence—from the
knowledge clinicians gain from treating their patient
populations to new research being discovered from highly
organized randomized controlled trials (RCTs). . . . To help
clinicians compare the quality between the various sources
of evidence, Dr. David Sackett, MD, popularized the
evidence-based medicine pyramid.68
The evidence-based medicine pyramid recognizes four types of evidence that
physicians must wade through to find the best information out there.69 Third,
Dr. Haughom notes that the physician must appraise the evidence to make
sure it is applicable to the patient(s) being considered.70 Fourth, the physician
applies the evidence to her practice of medicine on a regular basis.71 “If the
evidence passes the appraisal step and adds value to the practice of medicine,
then clinicians can incorporate the new knowledge into their daily clinical
practice.”72 Finally, the physician must assess her performance to ensure that
best outcomes are being consistently achieved.73 An evidence-based standard
of care that follows these steps can lower medical costs and help achieve more
efficient patient care in the United States.74 Three-parent IVF, along with
67

Id.
Id. (“[In the evidence-based pyramid,] the top level is the strongest because it underwent
a systematic review process and meta-analysis. Evidence in the lowest is the weakest because
it is primarily based on opinions and small sample sizes, which increases room for error.”).
69
Id. The levels of evidence in the evidence-based pyramid are as follows: The first level is
considered to be “the gold standard,” RCTs. Id. These RCTs are “free from any bias that
might otherwise be introduced by the people involved.” Id. Level two consists of evidence
from controlled trials without randomization and other relevant studies. Id. This level is not
as reliable as the first level, but is still quite reliable. Id. The third level of evidence is based
largely on expert opinions and has a large margin for errors. Id. The fourth and final level of
evidence on the pyramid is evidence that is based on personal experiences. Id. Level three
and four seem to makeup the custom-based standard of care when put together. Id.
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Id.
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Id.
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Id.
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Id.
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regular IVF, requires such a standard due to the sensitive and technical nature
of the procedure. Patients are required to sign an informed consent form for
each and every medical procedure to be performed. That begs the question:
What does being informed actually mean in the context of the medical
profession? The next section deals with two different standards that exist and
how they could affect three-parent IVF procedures in the future.
B.

Informed Consent: Paternalistic or Reasonable Patient?

A person’s body is her temple.75 It is a general norm in American
society that people must consent to activities—especially those that deal with
the body76—and visiting the doctor is no exception to that rule.
The doctrine of informed consent developed out of strong
judicial deference to individual autonomy, reflecting a
prevalent belief in American jurisprudence that an individual
has a right to be free from nonconsensual interference with
his or her person, and a basic moral principle that it is wrong
to force another to act against his or her will.77
At this point, some historical perspective on how informed consent
has evolved over the years seems proper. Jay Katz,78 physician and law

The last several decades of public health research have revealed that
customary care can actually be “bad” patient care. Customary care can lead
to misuse and underuse of the delivery of healthcare. . . . The quality and
cost problems with the customary care model have led to new national
initiatives to move the United States toward a modern, evidence-based
model of medical practice . . . .
Id. at 889, 899.
75
1 Corinthians 6:19 (“Do you not know that your body is a temple of the Holy Spirit who
is in you, whom you have received from God? You are not your own.”).
76
Schloendorff v. Soc’y of New York Hosp., 211 N.Y. 125, 129 (1914) (“Every human being
of adult years and sound mind has a right to determine what shall be done with his own
body.”).
77
FURROW ET AL., supra note 56, at 310.
78
Yale Law School Mourns Professor Jay Katz; Read Dean Koh Memorial Remarks, YALE
L. SCH. (Nov. 17, 2008), https://law.yale.edu/yls-today/news/yale-law-school-mourns-prof
essor-jay-katz-read-dean-koh-memorial-remarks. Yale Law School held a memorial service
in Jay Katz’ memory and an article was written detailing his remarkable life:
[Jay Katz] graduated from the University of Vermont in 1944, and earned
an M.D. from Harvard Medical School in 1949. After completing his
internship and residency in New York, Katz served as 1st Lieutenant and
Captain at the USAF Hospital at Maxwell Air Force Base in Alabama. He
came to Yale in 1953 and was soon named Chief Resident of the outpatient
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professor, authored The Silent World of Doctor and Patient. He stated:
“[D]isclosure and consent, except in the most rudimentary fashion, are
obligations alien to medical thinking and practice.”79 Historically, the
standards of consent primarily served as the basis for physicians to impose
their will, essentially forcing the patients to agree with their physicians’
treatment plans.80 The judiciary created the doctrine of informed consent,
which moved, according to Katz, through three distinct eras of evolution
before reaching its modern iteration.81 The first era simply required the
physician to tell the patient which course of treatment would be taken and
nothing more.82 This era can be roughly traced to the mid-twentieth century.83
The second era of informed consent saw the arrival of patient inclusion,
requiring physicians to give patients alternative treatment options along with
any risks associated with those options.84 This era lasted until the early
1970s.85 The third era—the current state of informed consent—has changed
very little from the previous one, in that physicians are required to give
patients all available treatment options and all accompanying risks.86
The first case to mention informed consent was Salgo v. Leland
Stanford Jr. University Board of Trustees in 1957.87 Justice Bray stated in the
majority opinion:
A physician violates his duty to his patient and subjects
himself to liability if he withholds any facts which are
necessary to form the basis of an intelligent consent by the
patient to the proposed treatment. A physician may not
clinic at the School of Medicine. Katz began teaching psychiatry at Yale in
1955 and psychiatry and law in 1958 when he was named Assistant
Professor of Psychiatry and Law at Yale University. . . . He was a leader in
the area of reproductive technology law and ethics and was an outspoken
opponent of the criminal prosecution of pregnant women, citing privacy
and equal protection concerns.
Id.
79
FURROW ET AL., supra note 56, at 311 (quoting JAY KATZ, THE SILENT WORLD OF DOCTOR
AND PATIENT 1 (1984)).
80
Id.
81
Id.
82
Id.
83
Id.
84
Id.
85
Id.
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Id.
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See generally Salgo v. Leland Stanford Jr. Univ. Bd. of Tr., 154 Cal.App.2d 560 (1957).
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minimize the known dangers of a procedure or operation in
order to induce his patient’s consent.88
Generally speaking, the disclosure requirement means physicians must
inform the patient of all available treatment options and any risks and benefits
associated with them.89 Further, it must include any alternative treatment
options that are available, as well as the potential risks and benefits that flow
from those alternatives.90 Lastly, it is essential to include the option of no
treatment at all, followed by a similar risk-benefit analysis.91
There are two models of informed consent, and they conflict with one
another. The first standard is known as the “paternalistic” or physician-based
standard, which is closely related to the customary care model.92 It is
grounded in profession uniformity and physician preference.93 The second
standard is known as the “reasonable patient” standard, where the patient’s
values and preferences are integrated into the decision-making process.94
1.
Physician-based standard, a.k.a. the paternalistic standard.
A majority of states have adopted the physician-based standard as the
standard for the disclosure requirement of informed consent.95 It is rooted in
the notion that the medical practice field needs to be uniform and consistent
so that doctors are able to advance their patients’ best interests in the most
efficient and safe manner possible.96 It requires expert testimony so doctors
do not need to concern “themselves with the risk that an uninformed lay jury
will later decide they acted improperly.”97 The majority of jurisdictions that
have adopted this as the standard to disclosure require a plaintiff to show two
things: that a reasonable doctor similarly situated would make the disclosure,
and that the doctor did not comply with this standard.98
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Id. at 578.
Suzanne K. Ketler, Note, The Rebirth of Informed Consent: A Cultural Analysis of the
Informed Consent Doctrine After Schreiber v. Physicians Insurance Co. of Wisconsin, 95
NW. U. L. REV. 1029, 1037 (2001).
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Id. at 314.
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2.
Reasonable patient standard. The reasonable patient standard
rebuts the majority view. The landmark case, Canterbury v. Spence, held that
the reasonable patient standard was the most effective standard, with the court
stating that “[w]e do not agree that the patient’s cause of action is dependent
upon the existence and nonperformance of a relevant professional
tradition.”99 The Canterbury court emphasized that each patient has specific
needs that are distinct and separate from other patients—thus the need for a
reasonable patient disclosure standard.100 In Wheeldon v. Madison, the court
concluded that the physician-based standard may conflict with the patient’s
specific needs.101 The Wheeldon court stated: “[W]e adopt the Canterbury v.
Spence rule that the standard measuring the performance of the physician’s
duty to disclose is conduct which is reasonable under the circumstances.”102
Even though the physician-based standard is currently followed by a majority
of states, the reasonable patient standard is quickly approaching a majority
position.103
III.

CURRENT CLIMATE FOR SAFETY REGULATION IN THE UNITED STATES

Three-parent IVF requires the use and manipulation of human-based
products; therefore, great care and diligence are required to ensure patient
safety. There are many federal agencies that oversee the human-based
product industry to make sure that safety is the number one priority of
medical providers.
The process of administering three-parent IVF, or regular IVF for that
matter, requires multiple steps and has many different layers of safety
regulation. First, there are technologies (such as devices and software) used
in fertility treatment that are governed by the FDA.104 It also regulates the
safety of tissue-based products, including donated eggs and semen.105
Second, there are laboratory tests performed on human tissues (such as eggs
and semen), which are governed under the Clinical Laboratory Improvement
Amendments (CLIA).106 Third, there are safety regulations in place for
techniques in the practice of medicine that are regulated by the individual
states under their police powers.107 Since safety is always a top priority when
99

Canterbury v. Spence, 464 F.2d 772, 783 (D.C. Cir. 1972).
Id.
101
Wheeldon v. Madison, 374 N.W.2d 367, 374 (S.D. 1985).
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See infra Part III.B.
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See infra Part III.C.
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it comes to performing medical procedures, current safety regulations must
be applied to three-parent IVF.
A.

FDA Safety Regulations for Human-Based Products

The regulation of reproductive technologies seems to be an area from
which the law tends to shy away: history has revealed that regulating
reproductive health is a particularly sensitive topic.108 At first glance,
reproductive technologies regulation seems to be something that should fall
to the individual states so they can protect their citizens’ health and
welfare.109 However, states rarely oversee reproductive technologies. The
FDA is responsible for safety regulation under the Public Health Service Act
(PHSA), which means the FDA regulates reproductive technologies, not the
individual states themselves.110
Three-parent IVF would fall directly under the FDA’s safety
regulations because the procedure deals with human-based products—semen
and eggs—that are manipulated in laboratories.111 Proper screening protocols
for eligible patients and donors is of paramount importance to avoid the
spread of communicable diseases. The FDA regulates safety in all of these
areas.
The FDA currently regulates human tissue-based products,112 which
consist of the following: “human cells or tissue intended for implantation,
transplantation, infusion, or transfer into a human recipient.”113 Examples of
human tissue that fit within the FDA’s regulatory responsibility are “bone,
skin, corneas, ligaments, tendons, dura mater, heart valves, hematopoietic
stem/progenitor cells, . . . oocytes, and semen.”114
The purpose of FDA tissue regulation is “to create an electronic
registration and listing system for establishments that manufacture human
cells, tissues, and cellular and tissue-based products . . . and to establish
108

See Lawrence v. Texas, 539 U.S. 558 (2003); Bellotti v. Baird, 443 U.S. 622 (1979); Roe
v. Wade, 410 U.S. 113 (1973); Griswold v. Connecticut, 381 U.S. 479 (1965).
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Tandice Ossareh, Would You Like Blue Eyes with That? A Fundamental Right to Genetic
Modification of Embryos, 117 COLUM. L. REV. 729, 734–35 (2017).
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Id. at 735.
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Tissue and Tissue Product Questions and Answers, U.S. FOOD & DRUG ADMIN. (Feb.
2, 2018), https://www .fda.gov/BiologicsBloodVaccines/TissueTissueProducts/Questionsab
outTissues/ucm101559.htm.
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donor-eligibility, current good tissue practice, and other procedures to
prevent the introduction, transmission, and spread of communicable diseases
by [tissue-based products].”115 It will be imperative that three-parent IVF
donors and patients alike are adequately screened for eligibility. This safety
regulation will help form the basis for the screening protocol for three-parent
IVF procedures. The FDA should look to current screening protocols in place
for regular IVF when deciding proper protocols to implement for three-parent
IVF.
The FDA takes a risk-based approach to its regulation of tissue-based
products with three goals in mind.116 First, the regulation seeks to “limit[] the
risk of transmission of communicable disease from donors to recipients.”117
Second, it “establish[es] manufacturing practices that minimize the risk of
contamination.”118 Finally, it “requir[es] an appropriate demonstration of
safety and effectiveness for cells and tissues that present greater risks due to
their processing or their use.”119 Limiting the transmission of communicable
diseases and lowering the risk of contamination will be important goals when
dealing with three-parent IVF. The procedure is quite invasive and
technical—even more technical than regular IVF. Therefore, these three
goals should be of the utmost importance for the FDA when determining a
risk level to associate with three-parent IVF.
The main objective and focus for the FDA is to limit the transmission
of communicable diseases. It is with this objective in mind that it applies
safety regulations to the human tissue-based product industry. Three-parent
IVF should and will be required to meet all FDA regulations and guidelines
in order to ensure patient safety.
B.

Procedures Performed in Laboratories are Governed by CLIA

Human-based products are regulated and screened for safety by the
FDA, but the regulation does not stop there. These human-based products are
manufactured and manipulated inside medical laboratories, and there are
separate regulations applied to these individual laboratories under CLIA. This
section will discuss these laboratory safety regulations and their importance
to three-parent IVF.
115
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The world is seeing a rapid advancement in technology, and its reach
has broad implications. Health care delivery is turning to a model of
“personalized medicine,” which fosters more predictability and efficiency.120
“U.S. laboratories that process human samples for health care treatment or
prevention are subject to federal, state, and professional organization
standards and regulations.”121 Although CLIA is the federal regulatory
standard, it does not preempt heightened state standards.122 If a state chooses
to implement standards that exceed CLIA, it is free to do so without objection
from the federal regulatory bodies.123
Diagnostic testing helps health care providers screen for or
monitor specific diseases or conditions. It also helps assess
patient health to make clinical decisions for patient care. . . .
[CLIA] regulate[s] laboratory testing and require[s] clinical
laboratories to be certificated by their state as well as the
Center for Medicare and Medicaid Services (CMS) before
they can accept human samples for diagnostic testing.
Laboratories can obtain multiple types of CLIA certificates,
based on the kinds of diagnostic tests they conduct.124
The CLIA program’s main objective is to ensure both universal quality
control over laboratory operations and the accuracy, proficiency, timeliness,
and reliability of patient test results.125 Laboratories that are regulated by
CLIA are defined as “clinical laborator[ies].”126 The broad definition of
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MICHAEL J. MALINOWSKI & ANDREA NEAL, Regulation of Commercial Laboratories, in
BIOTECHNOLOGY: LAW, BUS., & REG. 171 (2016).
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Clinical Laboratory Improvement Amendments (CLIA), U.S. FOOD & DRUG ADMIN.,
https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/IVDRegulatoryAssist
ance/ucm124105.htm (last visited Feb. 24, 2018).
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MALINOWSKI & NEAL, supra note 120, at 172.
126
The CLIA definition of what constitutes a “clinical laboratory” is as follows:
A facility for the biological, microbiological, serological, chemical,
immunohematological,
hematological,
biophysical,
cytological,
pathological, or other examination of materials derived from the human
body for the purpose of providing information for the diagnosis,
prevention or treatment of any disease or impairment of, or the assessment
of the health of, human beings.
Id. at 171.
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clinical laboratory includes hospitals, private physician offices, and all other
clinical laboratories that are not engaged solely in research.127
Every laboratory that falls within the definition of a “clinical
laboratory” must be CLIA certified.128 CMS is primarily responsible for
implementing the CLIA program, but the administration of CLIA is not the
sole responsibility of one single department.129 Instead, it is a combination of
multiple federal agencies that are needed to administer CLIA in an efficient
manner.130
The three federal agencies that help administer CLIA are CMS, FDA,
and the Centers for Disease Control (CDC).131CMS is responsible for issuing
laboratory certificates, collecting user fees, conducting site inspections,
approving private accreditation organizations for performing site inspections,
approving state exemption applications, monitoring laboratory performance,
and publishing CLIA rules and regulations.132 FDA is responsible for
categorizing laboratory tests based on complexity and reviewing requests for
waivers.133 CDC is responsible for providing analysis, research, and technical
assistance to laboratories; developing technical standards and laboratory
practice guidelines; conducting laboratory quality improvement studies; and
developing and distributing professional information and educational
resources.134 CMS lacks the resources to oversee all laboratories in the United
States, so it approves private organizations to act as CLIA accreditation
entities.135 By statute, CMS must follow certain criteria when selecting a
private accreditation organization.136 To date, CMS has approved only seven
CLIA accreditation organizations.137
CLIA regulation is not geographical in scope; in fact, geography does
not even play any role in CLIA regulation.138 Instead, CLIA regulates on the
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basis of its complexity model—the higher the risk, the more stringent the
regulation.139 A laboratory seeking CLIA certification is evaluated using a
risk scorecard that lists seven criteria.140 Based on the results from the
complexity scorecard’s criteria, CMS will apply the requisite regulatory
standards to that particular laboratory. Three-parent IVF will likely receive a
high complexity score due to its invasive and technical nature, leading to
tougher regulations. CLIA will ensure that three-parent IVF is administered
in a safe and healthy environment each and every time.
C.

Medical Malpractice is Governed by the Individual States

Practicing physicians are primarily regulated by their respective
states. States govern and regulate the practice of medicine because it
directly relates to the health and general welfare of their citizens.142 Fertility
physicians who perform three-parent IVF procedures will be required to
adhere to their states’ procedures and policies concerning the practice of
fertility medicine.143 As mentioned before, three-parent IVF is a procedure
141

139
140

Id.
The CLIA complexity scorecard criteria are as follows:
(1) Knowledge: the degree of scientific and technical knowledge that is
required to perform the test; (2) Training and experience: the degree of
experience required for the pre-analytical, analytical, and post-analytical
phases of the testing process; (3) Reagents and materials: the extent to
which reagents and materials used in the test process or system are
generally stable and reliable or require special handling, precautions, and
storage conditions; (4) Characteristics of operational steps: the extent to
which steps in the testing process are automatically executed and
otherwise easily controlled or require close monitoring, special specimen
preparation, temperature control, timing, extensive calculations, and other
precautions; (5) Calibration, quality, and control, and proficiency testing
materials: the stability and availability of these materials; (6) Test system
troubleshooting and equipment maintenance: the extent to which test
system troubleshooting is automatic or self-correcting and requires
minimal judgment, or requires decision making and direct intervention; (7)
Interpretation and judgment: the level or interpretation and judgment
required to perform pre-analytic, analytic, and post-analytic processes to
resolve problems.

Id. at 177–79.
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visited Feb. 24, 2018).
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with multiple steps—each step with its own set of safety regulations.144 This
section will discuss the steps that are necessary to provide adequate health
care to patients and how negligence principles dominate the practice of
medicine.
The relationship between a doctor and patient is an intimate one.
Patients oftentimes trust their doctor completely and, without reservation,
agree to her recommendations regarding treatment. This surely seems logical
because the doctor has been through medical school and is well-versed in the
human body and its ailments. The average person is not comfortable with
self-diagnosis, so visiting the doctor’s office is essential for health and wellbeing. What happens when that trusted doctor makes a critical mistake while
treating her patient? Is she liable for her actions? The short answer: it
depends.
In order to find liability, a number of factors must be present. There
must be an adequate doctor–patient relationship.145 This relationship is
developed by implied and express contracts between doctor and patient.146
Doctors expressly contract with patients in many different situations, such as
when an orthopedic surgeon expressly contracts to perform orthoscopic knee
surgery or when an ophthalmologist expressly contracts to perform a surgery
for cataracts. Both of these situations require the doctor and patient to enter
into an express contract with one another, thus creating the adequate doctor–
patient relationship. Express contracts are not the only means to develop this
doctor–patient relationship; in fact, they are not even the dominant method.147
“The vast majority of contracts in the field between healthcare professionals
and their patients are implied contracts.”148 For example, when a patient visits
a doctor’s office, the patient is essentially offering to enter into a contract
with the doctor.149 An implied contract is created once the doctor agrees to
evaluate the patient.150
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“The liability of health care providers is governed by general
negligence principles. Malpractice is usually defined as unskillful practice
resulting in injury to the patient, a failure to exercise the ‘required degree of
care, skill and diligence’ under the circumstances.”151 Each individual state,
not the federal government, regulates medical-malpractice claims among its
physicians.152
Under state law, a patient may pursue a civil claim against
physicians or other health care providers, called medical
liability or medical malpractice, if the health care provider
causes injury or death to the patient through a negligent act or
omission. To recover damages, the patient must establish: (1)
The physician owed a duty to the patient; (2) The standard of
care and that the physician violated that standard; (3) A
compensable injury; and (4) The violation of the standard of
care caused the harm suffered by the patient. 153
Three-parent IVF claims will likely be primarily rooted in negligence
principles, although contract claims will always persist among fertility
plaintiffs with the lack of defined remedies available to them.
The real problem with medical malpractice is that it is unavailable to
a vast majority of fertility plaintiffs due to its high costs. A physician’s
medical-malpractice insurance company will likely have a team of lawyers
that can defend any lawsuit that comes its way. Unfortunately, the same
cannot be said for most fertility plaintiffs. Money seems to put up an
insurmountable barrier, due to most fertility plaintiffs’ inability to pay for the
high cost of medical-malpractice litigation.
Medical malpractice has far-reaching effects. Patients, and the
healthcare industry as a whole, are greatly affected by the inefficient medicalmalpractice system in the United States.154 Patients are affected in many
different ways, which can include reluctance to seek out medical help due to
negligence claims towards a physician or hospital.155 Such malpractice suits
could impede the trust and openness in the doctor-patient relationship, which
151
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is foundational to the efficient delivery of healthcare in the United States.156
Generally, physicians purchase medical-malpractice insurance, as most
physicians do not possess the necessary resources to adequately defend a
medical-malpractice lawsuit on their own.157
Any and every system in the modern world seems to have a common
overarching concern—efficiency. Dr. Ezekiel Emanuel158 believes there is an
efficiency problem with the medical-malpractice system in the United States
that is largely due to defensive medicine practices,159 stating that “[o]ne of
the biggest concerns for physicians is medical malpractice. It agitates them
so much that it is often hard for them to focus on anything else, and it is not
hard to be sympathetic to their concerns.”160 Dr. Emanuel goes on to say,
“[m]any physicians are convinced that the high rate of medical-malpractice
suits encourage high levels of defensive medicine and excessive costs, such
as MRIs of the head after mild trauma that are unnecessary according to
professional guidelines but are done just in case of a lawsuit.”161
This connection between exorbitant health care costs and the fear of
being sued is easily understood. Aside from being expensive for physicians,
the medical-malpractice system cripples the patient. There are three general
goals, or purposes, that the medical-malpractice system aims to accomplish:
first, to make sure that patients who are injured by a physician’s negligence
are adequately compensated in a reasonable time frame; second, to ensure
156
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accountability among physicians, hospitals, and other health care providers;
and third, to improve the quality of health care by deterring negligent
behavior from physicians and other health care providers.162
The inefficiency problem of the medical-malpractice system is
harmful to fertility plaintiffs around the country. Harvard researchers
conducted a study that looked into just how inefficient medical malpractice
truly is. The study involved more than 30,000 medical records in the state of
New York and came to the conclusion that “97% of the time when a physician
or hospital commits a mistake that harms a patient, there is no lawsuit.”163
Dr. Emanuel explained:
The malpractice system is . . . not efficient. . . . [T]he average
time to settle a malpractice lawsuit is 20.3 months. Further,
only about 40 cents of every dollar in malpractice premiums
paid by physicians goes to injured patients; the rest is absorbed
in administrative and litigation costs and insurance company
profits.164
The inefficiency of the medical-malpractice system in the United
States is harmful to both physicians and patients alike. The three general
goals of the medical-malpractice system (timely compensation,
accountability, and deterrence) are not being met; therefore, there is a need
for medical-malpractice reform in the United States. Until this reform can
take place, three-parent IVF will need something to ensure remedies for
injured fertility patients.
IV.

TOWARD A SOLUTION: THREE-PARENT IVF AND MEDICAL
MALPRACTICE IN THE UNITED STATES

The law is usually slow when dealing with new developments in
technology.165 There are currently no legal theories or claims that are
available specifically for IVF plaintiffs: therefore, no claims will exist for
three-parent IVF plaintiffs, either.166 Legal practitioners often use existing
legal theories, such as tort law and contract law theory, to deal with new
162
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technological developments.167 For example, an IVF plaintiff will oftentimes
claim breach of contract when seeking damages.168 Legislation is currently
silent on the specific legal remedies that are available to IVF plaintiffs, hence
the need for the application of other legal theories. The immediate need is for
specific legislation addressing IVF liability in the United States; in the future,
three-parent IVF liability must also be addressed. Regular IVF and threeparent IVF liability should be treated differently, as three-parent IVF
procedures are riskier and more complex. The science behind three-parent
IVF is also in its infancy, unlike regular IVF, so considerable precautions
should be taken as the law moves forward to deal with what liability to assess.
This section will recommend legislation addressing three-parent IVF liability
in regards to the following: (1) the standard of care given by physicians; (2)
the informed consent standard imposed on physicians; and (3) the medicalmalpractice arena concerning three-parent IVF procedures—specifically the
implementation of a fertility court.
A.

Recommendations for Three-Parent IVF in the United States

1.
Implement three-parent IVF as a clinical trial to conduct
research. Three-parent IVF is in its infancy, and much research is needed to
ensure that it is reasonably safe. The lack of empirical evidence to show that
three-parent IVF is safe is a primary reason for countries holding back from
legalizing the procedure.169 Another reason is the argument that three-parent
IVF could lead to “designer babies.”170 To date, the United Kingdom is the
only country that has legalized the procedure.171 Other countries, such as
Mexico and Ukraine, are silent on the procedure, which is likely part of the
167
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reason that fertility physicians have performed procedures in those countries.
Legislation in the United States is unlikely to occur in the near future, at least
until more rigorous testing and research can be conducted on three-parent
IVF’s safety and effectiveness.
However, this should not prevent women who suffer from mitochondrial disease from having healthy children in the United States. If they so
choose, the option should be available to them within the borders of the
United States before legislation fully legalizes the procedure. This Comment
recommends that three-parent IVF be implemented in the United States as a
clinical trial172 to procure the necessary data required to make an educated
decision on proper legislation going forward. Those who choose to have a
child using the three-parent IVF procedure in the United States shall
participate (as a patient in the clinical trial) in a follow-up program, primarily
for purposes of monitoring the child into adulthood. This will allow scientists
and researchers to assess and monitor risks and outcomes, with the long-term
goal of gathering enough empirical evidence to write legislation to formally
legalize three-parent IVF in the United States as a fertility treatment.
2.
The need for an evidence-based standard of care for threeparent IVF procedures in the United States. Three-parent IVF is new,
innovative, and groundbreaking in fertility medicine. A medical standard of
care needs to be able to keep up with the implementation of such a procedure,
and the customary care standard is not sufficient to adequately serve the
purposes of three-parent IVF. The customary care model of medical practice
is based on physician preferences that are grounded in tradition, opinion, or
clinical experience and not on objective, scientific evidence.173 It is quite
evident that this standard will fall short, because there will be no clinical
172
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experience or tradition of three-parent IVF from which physicians can glean
a standard. Three-parent IVF desperately needs an evidence-based standard
to be implemented because it will ensure that objective, scientific evidence
will be properly considered in the decision-making process by physicians
when treating patients. Evidence-based medicine relies heavily on scientific
data to allow physicians to make informed decisions regarding patient care.
Skeptics will argue that this will create a problem in courts dealing with threeparent IVF cases, since scientific data will be sparse in the beginning stages
of clinical trials.174 Although it is true that three-parent IVF has limited
scientific evidence of its effectiveness and safety to date, this hurdle will be
overcome by looking to other countries around the world, including the
United Kingdom, to see clinical outcomes and safety.
3.
Informed consent standards for three-parent IVF: the
reasonable patient standard over paternalism. Patients are increasingly
becoming more involved with their own care.175 “[H]ealth care leaders are

174
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focused more than ever on patient engagement as a key to driving down costs
and improving outcomes.”176 Fertility treatment, in particular, is a sensitive
topic to discuss, and a woman who consents to a procedure as intimate as
three-parent IVF must be afforded the right to be involved in her care every
step of the way. The only standard that can adequately meet this burden is the
reasonable patient standard. In order for this standard to be fully effective,
the healthcare system must define a specific role for the patient within the
delivery of care.177 In essence, we need to define the role of the patient as a
person with a job:178
If the patient is to have a job in the care-delivery process, we
must apply the same principles of intentional work design to
their jobs as we do to those of physicians and clinical staff. . .
.
We know from classic management theory . . . applied and
tested in other service-industry contexts what good job design
looks like. Well-designed jobs, for example, give individuals
a clearly defined role to play with sufficient autonomy and
regular performance feedback built in. This not only allows
people to execute tasks effectively but also gives them a sense
of meaning and satisfaction in their work by seeing the
connection between their efforts and outcomes.179
It is important that patients are given the opportunity to play a meaningful
role in the administration of three-parent IVF because, like most ART
procedures, it will likely include very personal and patient-specific needs.
Medical professionals are some of the most skilled and valuable
people in society. But just as with any other profession, they are not without
fault. As discussed earlier, physicians make mistakes and these mistakes can
oftentimes lead to injuries—both physical and psychological—to their
patients. The manner in which these injuries are remedied must be equitable
for each and every patient, because injured patients should not be required to
live with an injury without just compensation. Since filing a medicalmalpractice lawsuit can be costly, to the point of being out of reach for some
patients due to cost, there needs to be an alternative way to reach equitable
solutions for all fertility plaintiffs. This Comment proposes the establishment
176
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of a fertility court within the United States Court of Federal Claims to provide
a no-fault system for injured fertility plaintiffs who are seeking compensation
for their injuries.
B.

A Lesson Learned from Vaccines: A Need for Fertility Court

It is no secret that filing a medical-malpractice lawsuit can be
expensive. So many would-be plaintiffs choose not to file suit due to the
inherent risks that run with filing such a lawsuit. These are people who have
suffered real and cognizable injuries—yet they choose to forgo compensation
due to the costly nature and uncertainty of a medical-malpractice lawsuit.
This generally limits injury awards in medical-malpractice cases to the upperclass plaintiffs who have the money to file these suits. In the 1980s,
pharmaceutical companies were being hit hard with lawsuits over select
childhood vaccines.180 These lawsuits created uncertainty regarding vaccine
shortages, with the fear that preventable diseases would make a resurgence if
vaccine companies stopped manufacturing vaccines.181 In 1986, the
implementation of the National Vaccine Injury Compensation Program
(NVICP)182 attempted to remedy this dilemma by providing financial
compensation to plaintiffs who filed a petition with the United States Court
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of Federal Claims,183 and were found to have been injured by a NVICPcovered vaccine.184 The NVICP provides a no-fault resolution for vaccine
injury petitions.185 “Congress intended that the Vaccine Program provide
individuals a swift, flexible, and less adversarial alternative to the often costly
and lengthy civil arena of traditional tort litigation.”186 The vaccine court fund
was created by the administration of a 75-cent tax for every dose of a vaccine
sold by the pharmaceutical companies.187 Vaccine courts have encouraged
pharmaceutical companies to continue developing much needed vaccines by
largely decreasing their litigation liability. It also provides a remedy for
injured plaintiffs, who may not have the necessary funds to file a lawsuit, to
seek compensation for their injuries caused by vaccines.
This Comment proposes the implementation of a fertility court within
the United States Federal Court of Claims to combat the same inequities that
the vaccine court dealt and still deals with on a regular basis. Like vaccine
court, it will operate as a no-fault court. Three-parent IVF requires such a
court, along with other ART procedures, to ensure that fertility plaintiffs are
justly compensated for their injuries and to reduce the occurrence of fertility
183
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malpractice litigation. An injured three-parent IVF patient should not be left
out in the cold due to her inability to finance a costly medical-malpractice
lawsuit. A fertility court will ensure that injured three-parent IVF patients
will always have an available remedy, regardless of financial or
socioeconomic status.
1.
Funding fertility court: a licensing fee to a federal fertility
fund. Vaccine court is funded by a taxing system where the pharmaceutical
companies pay a 75-cent tax for every dose of vaccine they sell. This
incentivizes the pharmaceutical companies to pass the cost to the consumers
through an increased vaccination price. It is proposed that Congress enact
legislation to require a “licensing fee” to be administered to patients by every
fertility physician who performs fertility treatment.
Fertility physicians who administer the three-parent IVF procedure in
the United States would charge their fertility patients a fee that would be
directly routed to a fertility court fund. The incentive for such a system will
be a two-way street. First, it incentivizes the physician to charge the fee
because she will be able to provide three-parent IVF procedures to patients
without adding cost to her own practice of medicine. Second, it incentivizes
the patient to pay the fee because she will have the opportunity to have the
procedure done at home in the United States, and she will have the peace of
mind that a fertility court will be there to support her if she is injured from
the procedure.
Funding fertility court this way will benefit both the physician and the
patient. As discussed earlier, defensive medicine practices are a prevalent
problem in the United States. The inefficient practice of defensive medicine
can largely be attributed to fear that a physician feels about looming medicalmalpractice lawsuits. A fertility court will help remedy defensive medicine
practices among fertility physicians by lowering their medical-malpractice
insurance premiums, as medical-malpractice litigation liability for ART
procedures will likely plummet due to the availability of a fertility court.
2.
A fertility court will lower medical malpractice insurance
premiums for fertility physicians by reducing their litigation liability.
Physicians who practice fertility medicine experience some of the most
outrageously high medical-malpractice premiums in the United States—
some paying as much as $195,000 annually in premium payments alone.188
188
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Routing a majority of fertility plaintiffs to a fertility court should drastically
lower the medical-malpractice premiums for fertility physicians, as the
litigation liability should lower significantly. Fertility physicians may be
hesitant to perform a three-parent IVF procedure because it could mean even
higher medical-malpractice insurance premiums due to the procedure’s
technical nature and infancy status. This concern is valid and would be
addressed by the implementation of a fertility court. Fertility physicians will
likely see their medical-malpractice insurance premiums lower because they
will have less exposure with the existence of a fertility court. Fertility
plaintiffs will have the option to file a claim with fertility court instead of
being required to hire an attorney to sue a medical-malpractice insurance
carrier, which is costly, time-consuming, and stressful.
In the 1980s, pharmaceutical companies that manufactured select
vaccines nearly stopped making them due to overexposure to litigation
liability. The implementation of a vaccine court significantly dropped that
liability and allowed pharmaceutical companies to continue manufacturing
important and life-saving vaccines—all of which would not have been
possible without a vaccine court.
The implementation of three-parent IVF in the United States needs to
be followed by the establishment of a fertility court, following in the
successful footsteps of the vaccine industry. Implementing three-parent IVF
without a fertility court would likely have negative consequences. It would
discourage fertility physicians from performing the procedure altogether, out
of fear of the possibility of increased medical-malpractice litigation. It would
also discourage patients from seeking out the procedure due to the inability
to remedy an injury, if one were to occur. Fertility court provides a solution
for both of these concerns.
CONCLUSION
Three-parent IVF is here and most likely to stay. The United Kingdom
has rung in a new era in fertility medicine by legalizing three-parent IVF—
giving women with mitochondrial disease new hope. Legislation in the
United States to regulate three-parent IVF as a clinical trial is necessary to
help rid the world of mitochondrial disease. The legislation must stress the
importance of safety regulations that are already in place for tissue donation
and transplantation.
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Three-parent IVF legislation is also needed to address the cost and
efficiency problems of the medical-malpractice system in the United States.
The benefits of implementing a fertility court would be two-fold. First, it
should drive down medical-malpractice premium payments for fertility
physicians, as their litigation liability will likely fall. Second, it should give
all fertility plaintiffs a viable option to be compensated for their injuries. The
importance and value of having a no-fault court system for three-parent IVF
and other fertility injuries should increase the efficiency and reduce the cost
of the medical-malpractice system in the United States.
This legislation will ensure that women, from all walks of life, who
suffer from mitochondrial disease can have the opportunity to rear and raise
their own genetic children. United States citizens should not be hindered
when it comes to the right to create a family. Legislation needs to reflect this
precious and sacred societal value.

